Intrinsiqs

Is Lixte Biotechnology Holdings, Inc. overvalued?

Lixte Biotechnology Holdings, Inc. (LIXT) — key valuation metrics and fundamentals.

No verdict
Price
$7.21
Fair value
Current P/E
Normal P/E
Market cap
$89.1M
Dividend yield
0.0%
Return on equity
-125.6%
Sector
Healthcare

See the full interactive analysis →

Fair value compares LIXT's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Aug 2026.